首页> 外文期刊>Behavioural Brain Research: An International Journal >Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model
【24h】

Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model

机译:致力于在经过验证的动物模型中改进对精神分裂症阴性症状的检测方法

获取原文
获取原文并翻译 | 示例
           

摘要

Negative symptoms in schizophrenia remain an unmet clinical need. There is no licensed treatment specifically for this debilitating aspect of the disorder and effect sizes of new therapies are too small to make an impact on quality of life and function. Negative symptoms are multifactorial but often considered in terms of two domains, expressive deficit incorporating blunted affect and poverty of speech and avolition incorporating asociality and lack of drive. There is a clear need for improved understanding of the neurobiology of negative symptoms which can be enabled through the use of carefully validated animal models. While there are several tests for assessing sociability in animals, tests for blunted affect in schizophrenia are currently lacking. Two paradigms have recently been developed for assessing negative affect of relevance to depression in rats. Here we assess their utility for studying negative symptoms in schizophrenia using our well validated model for schizophrenia of sub-chronic (sc) treatment with Phencyclidine (PCP) in adult female rats. Results demonstrate that sc PCP treatment produces a significant negative affect bias in response to a high value reward in the optimistic and affective bias tests. Our results are not easily explained by the known cognitive deficits induced by sc PCP and support the hypothesis of a negative affective bias in this model. We suggest that further refinement of these two tests will provide a means to investigate the neurobiological basis of negative affect in schizophrenia, thus supporting the assessment of efficacy of new targets for this currently untreated symptom domain. (C) 2016 Elsevier B.V. All rights reserved.
机译:精神分裂症的阴性症状仍未满足临床需求。没有专门针对这种令人衰弱的方面的许可疗法,新疗法的效果大小太小,无法影响生活质量和功能。负面症状是多因素的,但通常从两个方面来考虑,即表达力不足和情感迟钝,言语贫乏和社交能力不足以及缺乏动力。显然需要更好地了解阴性症状的神经生物学,这可以通过使用经过仔细验证的动物模型来实现。尽管有几种评估动物的社会交往能力的测试方法,但目前尚缺乏对精神分裂症钝化影响的测试方法。最近已经开发出两种范例,用于评估与抑郁症相关的大鼠的负面影响。在这里,我们使用成年雌性大鼠苯环利定(PCP)亚慢性(sc)治疗精神分裂症的经过验证的模型,评估了它们在研究精神分裂症阴性症状中的效用。结果表明,在乐观和情感偏见测试中,sc PCP治疗会产生显着的负面影响偏见,以响应高价值奖励。我们的结果不容易解释为由sc PCP引起的已知认知缺陷,并支持该模型中的负面情感偏见的假设。我们建议进一步完善这两个测试将提供一种手段,以调查精神分裂症负面影响的神经生物学基础,从而支持对当前尚未治疗的症状域的新靶标疗效进行评估。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号